Sol-Gel Technologies (NASDAQ:SLGL – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($2.13) EPS for the quarter, missing the consensus estimate of ($2.09) by ($0.04), Zacks reports. The firm had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.30 million. Sol-Gel Technologies had a negative return on equity of 11.80% and a negative net margin of 14.25%.
Sol-Gel Technologies Trading Down 2.6%
Shares of NASDAQ SLGL traded down $0.95 during midday trading on Thursday, reaching $35.09. 19,061 shares of the stock were exchanged, compared to its average volume of 22,531. The stock has a 50 day moving average price of $33.95 and a 200-day moving average price of $19.45. The company has a market capitalization of $97.76 million, a P/E ratio of -28.53 and a beta of 1.35. Sol-Gel Technologies has a 52-week low of $4.02 and a 52-week high of $52.26.
Wall Street Analyst Weigh In
SLGL has been the topic of a number of research analyst reports. HC Wainwright boosted their target price on Sol-Gel Technologies from $6.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, October 27th. Weiss Ratings restated a “hold (c-)” rating on shares of Sol-Gel Technologies in a research report on Wednesday, October 8th. Wall Street Zen lowered shares of Sol-Gel Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. Finally, Zacks Research raised shares of Sol-Gel Technologies to a “hold” rating in a research note on Tuesday, October 28th. One equities research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, Sol-Gel Technologies presently has a consensus rating of “Hold” and a consensus target price of $50.00.
About Sol-Gel Technologies
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Recommended Stories
- Five stocks we like better than Sol-Gel Technologies
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- NVIDIA Just Proved the AI Boom Is Bigger Than Anyone Thought
- How to find penny stocks to invest and trade
- Why Target Stock May Keep Falling Despite a 5% Dividend Yield
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Is Tesla Setting Up for a Year-End Rebound—or a Collapse?
Receive News & Ratings for Sol-Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol-Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
